Embecta (EMBC) - 2026 Q1 - Quarterly Results

Financial Performance - Reported revenues for Q1 FY 2026 were $261.2 million, a decrease of 0.3% from $261.9 million in Q1 FY 2025[4] - U.S. revenues decreased by 7.6% on both reported and adjusted constant currency basis, while international revenues increased by 8.4% on a reported basis[4] - Gross profit was $161.7 million with a margin of 61.9%, compared to $157.1 million and 60.0% in the prior year[4] - Operating income was $83.3 million, representing a margin of 31.9%, significantly up from $28.7 million and 11.0% in the prior year[4] - Net income was $44.1 million, with earnings per diluted share of $0.74, compared to $0.0 million in the prior year[4] - Adjusted EBITDA for the three months ended December 31, 2025, was $97.2 million, compared to $97.3 million in 2024, maintaining a stable performance[24] - GAAP gross profit increased to $161.7 million for the three months ended December 31, 2025, with a gross profit margin of 61.9%, up from 60.0% in 2024[25] - GAAP Operating Income for the three months ended December 31, 2025, was $83.3 million, compared to $28.7 million in 2024, representing a margin increase from 11.0% to 31.9%[28] - Adjusted Operating Income for the same period was $79.3 million, slightly down from $80.5 million in 2024, with a margin of 30.4%[28] - GAAP Net Income reached $44.1 million for Q4 2025, with an Adjusted Net Income of $42.3 million, up from $38.3 million in 2024[28] - Non-GAAP Free Cash Flow improved to $16.6 million in Q4 2025, compared to a negative $6.8 million in the same quarter of 2024[30] Debt and Financial Position - The company reduced debt by approximately $37.5 million during Q1 FY 2026, improving financial flexibility[5] - The company had approximately $204.4 million in cash and equivalents and $1.379 billion in outstanding debt as of December 31, 2025[12] - Total assets decreased from $1,090.9 million as of September 30, 2025, to $1,063.7 million as of December 31, 2025, a decline of approximately 2.5%[19] - Total current liabilities decreased from $261.5 million as of September 30, 2025, to $234.7 million as of December 31, 2025, a reduction of approximately 10.3%[19] - Cash and equivalents decreased from $225.5 million as of September 30, 2025, to $201.3 million as of December 31, 2025, a decline of about 10.7%[19] - Payments on long-term debt for the three months ended December 31, 2025, were $37.5 million, compared to $32.4 million in 2024, indicating an increase of 16.8%[21] Future Outlook - The company expects reported revenues for FY 2026 to be in the range of $1,071 million to $1,093 million, with an adjusted constant currency revenue growth of -2.0% to 0.0%[9] - A quarterly cash dividend of $0.15 per share was declared, payable on March 17, 2026[13] - The company is focused on expanding its product portfolio and maintaining its global leadership position in diabetes care[32] - Future strategies include enhancing financial flexibility through debt reduction and exploring strategic partnerships and acquisitions[32] - The company aims to transform into a broad-based medical supplies company serving chronic care patients and drug delivery partners[32] Operational Highlights - The company advanced over one third of more than 30 identified potential B2B generic partners into contract negotiations or executed contracts[5] - The company incurred one-time stand-up costs of approximately $4.8 million in Q4 2025, down from $10.4 million in Q4 2024[29] - The non-GAAP effective tax rate for Q4 2025 was 23.0%, compared to 25.0% in Q4 2024[29] - The basic weighted average number of shares outstanding increased to 58,796 thousand in Q4 2025 from 57,952 thousand in 2024[28]